Shopping Cart 0
Cart Subtotal
USD 0

Palatin Technologies Inc (PTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company's development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its clinical pipeline includes melanocortin receptor programs such as Bremelanotide MC4r Agonist for hypoactive sexual desire disorder, PL-8177 MC1r Agonist for inflammatory bowel disease and PL-8331 MC1/5r Agonist for anti-inflammatory ocular indications; and natriuretic peptide receptor programs including PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.

Palatin Technologies Inc (PTN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11

Licensing Agreements 12

Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12

Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14

Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16

Equity Offering 17

Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17

Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18

Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19

Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21

Palatin Raises USD20 Million in Private Placement of Warrants 23

Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25

Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27

Palatin Technologies Inc-Key Competitors 28

Palatin Technologies Inc-Key Employees 29

Palatin Technologies Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Sep 13, 2018: Palatin Technologies reports fourth quarter and fiscal year 2018 results 31

May 15, 2018: Palatin Technologies Announces Third Quarter Fiscal Year 2018 Results 34

Feb 12, 2018: Palatin Technologies Reports Second Quarter Fiscal Year 2018 Results 36

Nov 13, 2017: Palatin Technologies reports first quarter fiscal year 2018 results 38

Sep 25, 2017: Palatin Technologies Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 40

May 16, 2017: Palatin Technologies Reports Third Quarter Fiscal Year 2017 Results 42

Feb 09, 2017: Palatin Technologies Reports Second Quarter Fiscal Year 2017 Results 44

Corporate Communications 45

Sep 12, 2017: Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors 45

Product News 46

01/03/2018: Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis 46

Product Approvals 47

Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide 47

Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA 49

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women 50

Clinical Trials 51

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 51

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 52

Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease 53

Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist 54

Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting 55

Other Significant Developments 57

Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 57

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11

Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12

Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14

Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16

Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17

Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18

Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19

Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21

Palatin Raises USD20 Million in Private Placement of Warrants 23

Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25

Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27

Palatin Technologies Inc, Key Competitors 28

Palatin Technologies Inc, Key Employees 29

Palatin Technologies Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Palatin Technologies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company's development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its clinical pipeline includes melanocortin receptor programs such as Bremelanotide MC4r Agonist for hypoactive sexual desire disorder, PL-8177 MC1r Agonist for inflammatory bowel disease and PL-8331 MC1/5r Agonist for anti-inflammatory ocular indications; and natriuretic peptide receptor programs including PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.

Palatin Technologies Inc (PTN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11

Licensing Agreements 12

Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12

Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14

Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16

Equity Offering 17

Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17

Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18

Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19

Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21

Palatin Raises USD20 Million in Private Placement of Warrants 23

Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25

Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27

Palatin Technologies Inc-Key Competitors 28

Palatin Technologies Inc-Key Employees 29

Palatin Technologies Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Sep 13, 2018: Palatin Technologies reports fourth quarter and fiscal year 2018 results 31

May 15, 2018: Palatin Technologies Announces Third Quarter Fiscal Year 2018 Results 34

Feb 12, 2018: Palatin Technologies Reports Second Quarter Fiscal Year 2018 Results 36

Nov 13, 2017: Palatin Technologies reports first quarter fiscal year 2018 results 38

Sep 25, 2017: Palatin Technologies Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 40

May 16, 2017: Palatin Technologies Reports Third Quarter Fiscal Year 2017 Results 42

Feb 09, 2017: Palatin Technologies Reports Second Quarter Fiscal Year 2017 Results 44

Corporate Communications 45

Sep 12, 2017: Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors 45

Product News 46

01/03/2018: Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis 46

Product Approvals 47

Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide 47

Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA 49

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women 50

Clinical Trials 51

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 51

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 52

Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease 53

Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist 54

Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting 55

Other Significant Developments 57

Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 57

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Palatin Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11

Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12

Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14

Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16

Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17

Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18

Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19

Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21

Palatin Raises USD20 Million in Private Placement of Warrants 23

Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25

Palatin Technologies Completes Private Placement Of Common Stock And Warrants For USD 35 Million 27

Palatin Technologies Inc, Key Competitors 28

Palatin Technologies Inc, Key Employees 29

Palatin Technologies Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Palatin Technologies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.